News Releases

News Releases

Date Title
Mar 4, 2019 Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
Company Announces Additional Key Primary and Secondary Endpoints Further Supporting Vicinium ® Treatment Potential in High-Risk Non-Muscle Invasive Bladder Cancer Company on Track to Report Updated 12-Month Data from Phase 3 VISTA Trial of Vicinium in Mid-2019 Management to Host a Business Update
Feb 25, 2019 Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4,
Jan 3, 2019 Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer
Complete Response Rates from All Four Time Points in Carcinoma in Situ Patients In-line with Phase 2 Data Company to Host Conference Call Today, January 3 , at 8:30 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company advancing
Top